Skip to Content
Søg Menu

Real-World Treatment Patterns of Nivolumab + Cabozantinib Compared with Other 1L IO Combinations in mRCC

/ Cherrishe Brown-Bickerstaff / Jan Andreasen
ASCOGU25Nyrecancer

Cabozantinib Real-World Effectiveness in the Second-Line Setting of Metastatic Renal Cell Carcinoma

/ Martin Zarba / Jan Andreasen
ASCOGU25Nyrecancer
Sylvie Negrier

Cabozantinib Shows Promising Results in Treatment of Patients with Non-Locally Pretreated Brain Metastases from Renal Cell Carcinoma

/ Sylvie Negrier
ASCOGU25Nyrecancer Play the Video

Dansk studie afslører fordobling af nyrecancer-tilfælde

/ Johanne Ahrenfeldt / Jan Andreasen
ASCOGU25Nyrecancer

Norwegian Perspectives on Urogenital Cancer at ESMO 2024

/ BestPractice Nordic
ESMO24ProstatacancerNyrecancerBlærecancer

Rechallenge of IO/TKI in Second-Line After IO/TKI in First-Line Will Not Add Any Benefits

/ Sofie Pohl
Nyrecancer
Daniel Heinrich

Highlights from ESMO 2024: More Intelligent Choice of Treatment in the Future

/ Daniel Heinrich
ESMO24ProstatacancerNyrecancerBlærecancer Play the Video
Katriina Jalkanen

Belzutifan is Well-Tolerated and Might Be an Addition to a Standard of Care

/ Katriina Jalkanen
ESMO24Nyrecancer Play the Video
Umang Swami

Single-Agent Cabozantinib is Sufficient and Avoids Extra Toxicity in Metastatic Clear Cell Renal Cell Carcinoma Patients

/ Umang Swami
Nyrecancer Play the Video

Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma Receiving Checkpoint Inhibitors

/ Niels Fristrup
Nyrecancer

Nivolumab + Cabozantinib Remains Standard of Care in First-Line Treatment for Advanced Renal Cell Carcinoma

/ Sofie Pohl
Nyrecancer
Maria Teresa Bourlon

Nivolumab + Cabozantinib Remains Standard of Care in First-Line Treatment for Advanced Renal Cell Carcinoma

/ Maria Teresa Bourlon
Nyrecancer Play the Video
Hent flere
Back to top